LGVN.US Longeveron LLC

Healthcare Biotechnology USA Stocks
2.60 USD
Close of Nov 15, 2026
1.31 12.30
Market cap
USD 8.40M
P/E
-
P/B
1.78x
ROE
-479.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LGVN.US undervalued?

Graham number

The Graham number of Longeveron LLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Longeveron LLC fundamental analysis

No fundamental analysis for Longeveron LLC yet.

Longeveron LLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Longeveron LLC

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase…

Full company profile